Predictors of intrastent restenosis in the right coronary artery ostium. The ostium of the right coronary artery (RCA) presents certain histological aspects. Atherosclerotic and fibrotic plaques in this area contain an abundance of smooth muscle, collagen, and a certain degree of calcification, along with thicker adventitia. Additionally, it has certain anatomical aspects such as poor<a href="https://solaci.org/en/2023/06/16/intrastent-restenosis-in-ostial-lesions-in-the-right-coronary-artery-predictors-of-an-unfavorable-location/" title="Read more" >...</a>
Coronary Physiology after Aortic Valve Intervention
Impact of Aortic Valve Intervention on Coronary Flow Reserve Myocardial flow might be compromised in patients with severe aortic stenosis, which might be driven by CAD and concomitant atherosclerosis or a compromised capillary bed. Capillary circulation might be compromised by increased left ventricular mass (LVM) which in turn might alter coronary flow reserve (CFR). Multiple<a href="https://solaci.org/en/2023/02/27/coronary-physiology-after-aortic-valve-intervention/" title="Read more" >...</a>
Is Rehospitalization a Relevant Factor after Aortic Valve Replacement?
Patients with severe symptomatic aortic stenosis treated with aortic valve replacement might still present cardiac failure, even after successful procedures. According to some reports, the incidence of cardiac failure after TAVR varies between 9% and 24%. The prognostic relevance of rehospitalization in these patients has not been studied yet; in fact, it remains unclear whether<a href="https://solaci.org/en/2023/01/19/is-rehospitalization-a-relevant-factor-after-aortic-valve-replacement/" title="Read more" >...</a>
EuroPCR 2022 | Jenavalve Trilogy System: Valve for Severe Aortic Regurgitation
Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they have often been used to treat aortic regurgitation as an off-label indication. The Jenavalve Trilogy valve has recently received the CE Mark for aortic regurgitation and aortic stenosis. This study included 45 patients with severe AR. Primary end<a href="https://solaci.org/en/2022/05/23/europcr-2022-jenavalve-trilogy-system-valve-for-severe-aortic-regurgitation/" title="Read more" >...</a>
Avatar Trial: Is It Time to Use Surgical Aortic Valve Replacement in Asymptomatic Patients?
It is still unclear whether surgical aortic valve replacement (SAVR) is beneficial in asymptomatic patients with severe aortic stenosis (AS) and conserved left ventricular function (C1 indication according to AHA guidelines). The European American guidelines only recommend intervention in asymptomatic patient when there is ventricular compromise (ejection fraction <50%, class I indication) or with a<a href="https://solaci.org/en/2022/05/05/avatar-trial-is-it-time-to-use-surgical-aortic-valve-replacement-in-asymptomatic-patients/" title="Read more" >...</a>
TAVR vs Sutureless Surgical Aortic Valve Replacement in Low-Risk Patients
Sutureless surgical aortic valve replacement (SU-SAVR) has been designed to make surgical valve replacement easier and faster, especially compared against conventional biological valves which require multiple sutures; their rapid deployment translates into reduced cross-clamp and operative time. These valves shorten operating time and are less invasive than conventional surgical valves. Except for sternotomy incisions, they<a href="https://solaci.org/en/2021/11/19/tavr-vs-sutureless-surgical-aortic-valve-replacement-in-low-risk-patients/" title="Read more" >...</a>
SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection
Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Daniel Zanuttini (Arg.) presents “Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection”. This is the 8th clinical case presented by SOLACI Peripheral. The purpose of this space is to encourage and further the exchange of experiences<a href="https://solaci.org/en/2021/08/24/solaci-peripheral-type-ib-endoleak-correction-in-patient-after-minimally-invasive-hybrid-treatment-in-type-a-aortic-disection/" title="Read more" >...</a>
Asymptomatic Carotid Artery Stenosis: Do We Have All the Answers?
Advancements in therapies to reduce the impact of stroke in asymptomatic carotid artery stenosis have been hard to come by over the last decade. Several points of disagreement among published randomized trials prevented their information from being integrated into daily clinical practice. However, over the past 5 years, there has been some alignment, allowing for this<a href="https://solaci.org/en/2020/05/11/asymptomatic-carotid-artery-stenosis-do-we-have-all-the-answers/" title="Read more" >...</a>
Aortic Valvuloplasty as a Bridge to TAVR: Are We Wasting Our Time?
Doing a balloon aortic valvuloplasty can be a good way to “buy” time before a transcatheter aortic valve replacement (TAVR), according to a registry to be published this week in J Am Coll Cardiol Intv. This study analyzed the database of a whole country to find out the incidence, predictors and outcomes of balloon aortic<a href="https://solaci.org/en/2020/04/13/aortic-valvuloplasty-as-a-bridge-to-tavr-are-we-wasting-our-time/" title="Read more" >...</a>
More Favorable Evidence for TAVR in Severe Aortic Regurgitation
Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVR) was developed for aortic stenosis, but there is a significant number of patients with severe aortic regurgitation who still undergo this procedure as an off-label indication. Current evidence for this procedure in relation with this disease is growing, mainly due to good results obtained by different<a href="https://solaci.org/en/2018/07/27/more-favorable-evidence-for-tavr-in-severe-aortic-regurgitation/" title="Read more" >...</a>